Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Federica Carrieri
Institution:
University of Chieti-Pescara
Observed institutions:
University of Chieti-Pescara,
Azienda USL di Pescara,
University of Bologna
ORCID:
0009-0001-2117-3416
Observed ORCID:
0009-0001-2117-3416
OpenAlex ID:
A5047866594
Effectiveness and Tolerability of Once-Weekly GLP-1 Receptor Agonists in Clinical Practice: A Focus on Switching Between Once-Weekly Molecules in Type 2 Diabetes
2022
·
Giulia Di Dalmazi
, Sara Coluzzi
, et al.
·
Frontiers in Endocrinology
·
22
PDF
Oral Semaglutide in Routine Clinical Practice: Characteristics of People with Type 2 Diabetes Started on the Drug and Changes in Their Clinical Parameters after 24 Weeks of Treatment
2024
·
Maria Pompea Antonia Baldassarre
, Giulia Di Dalmazi
, et al.
·
Journal of Clinical Medicine
·
13
IDegLira for the Real-World Treatment of Type 2 Diabetes in Italy: Protocol and Interim Results from the REX Observational Study
2022
·
Gian Paolo Fadini
, Raffaella Buzzetti
, et al.
·
Diabetes Therapy
·
8
PDF
Real-world use of non-pregnancy-specific automated insulin delivery systems during gestation and delivery: a case series
2025
·
Federica Carrieri
, Maria Pompea Antonia Baldassarre
, et al.
·
BMC Pregnancy and Childbirth
·
3
Modulation of circulating extracellular vesicles by antihyperglycemic therapies: A pilot randomized controlled trial
2026
·
Maria Pompea Antonia Baldassarre
, Federica Carrieri
, et al.
·
Journal of Diabetes and its Complications
·
2
Optimizing Diabetes Management During Type 1 Diabetes Pregnancy with Automated Insulin Delivery Therapy: Clinical Impact and Economic Consequences in Spain
2026
·
Pilar I. Beato-Víbora
, Maria-Eleni Syleouni
, et al.
·
Diabetes Technology & Therapeutics
·
1
Serum FT3 levels and FT3/FT4 ratio as predictors for poor prognosis in hospitalized COVID-19 patients
2022
·
Marica Milo
, Dalmazi Giulia Di
, et al.
·
Endocrine Abstracts
·
1
Oral Semaglutide in Routine Clinical Practice: 24‐Month Real‐World Effectiveness, Persistence and Safety in Adults With Type 2 Diabetes
2026
·
Maria Pompea Antonia Baldassarre
, Giulia Di Dalmazi
, et al.
·
Diabetes Obesity and Metabolism
PDF
Author response for "Oral semaglutide in routine clinical practice: 24-month real-world effectiveness, persistence and safety in adults with type 2 diabetes"
2026
·
Maria Pompea Antonia Baldassarre
, Giulia Di Dalmazi
, et al.
·
Publons reviews and discussion
Sodium–glucose cotransporter 2 inhibitor-associated erythrocytosis in type 2 diabetes: a retrospective cohort study
2026
·
Maria Pompea Antonia Baldassarre
, Federica Carrieri
, et al.
·
Acta Diabetologica
PDF
Author response for "Oral semaglutide in routine clinical practice: 24-month real-world effectiveness, persistence and safety in adults with type 2 diabetes"
2026
·
Maria Pompea Antonia Baldassarre
, Giulia Di Dalmazi
, et al.
·
Publons reviews and discussion
HbA1c improvement in pregnant women with type 1 diabetes using the CamAPS FX automated insulin delivery ( AID ) system: Clinical and economic outcomes
2026
·
Maria‐Eleni Syleouni
, Tara T. M. Lee
, et al.
·
Diabetic Medicine
Invited commentary: Advancing the management of type 2 diabetes in pregnancy
2026
·
Federica Carrieri
, Eleanor M. Scott
, et al.
·
Diabetic Medicine
PDF
Diabete mellito indotto da inibitori dei checkpoint immunitari: un approccio tecnologico
2025
·
Federica Carrieri
, Sara Coluzzi
, et al.
·
il Diabete
PDF
A worldwide study to estimate the relative risk to develop type 2 Diabetes Mellitus because of atmospheric pollutants exposure
2025
·
Eleonora Aruffo
, Alessandra Mascitelli
, et al.
·
EGU General Assembly Conference Abstracts
Una finestra aperta sulla disfunzione endoteliale: il modello HUVEC
2024
·
Federica Carrieri
, Caterina Pipino
, et al.
·
il Diabete
PDF
Show more works
View as search
Works count:
16
Citation count:
50
H-index:
3
I10-index:
2
Year
Topic
Type